Stockscreener 앱 받기
46.48
5.21%
2.30
시장 영업 전:
46.00
-0.48
-1.03%
전일 마감가:
$44.18
열려 있는:
$46.59
하루 거래량:
414.25K
Relative Volume:
0.95
시가총액:
$2.24B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.59%
1개월 성능:
-3.45%
6개월 성능:
+209.04%
1년 성능:
+292.57%
1일 변동 폭
$44.43
$46.65
1주일 범위
$43.00
$47.27
52주 변동 폭
$6.71
$49.25
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
46.48 | 2.13B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks
MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat
Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union
MAZE Technical Analysis & ETF Price Forecast - Intellectia AI
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews
Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru
Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma
Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
MAZE Should I Buy - Intellectia AI
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit - MarketBeat
Frazier Life Sciences discloses Maze Therapeutics (MAZE) 9% ownership and warrants cap - Stock Titan
Bull Bear: What analysts say about Maze Therapeutics Inc stockGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Sahm
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on Strong Buy Ratings and 12.50% Upside Potential - DirectorsTalk Interviews
Maze Therapeutics Secures New $200 Million Loan Facility - The Globe and Mail
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - AOL.com
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews
Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada
Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat
Maze Therapeutics Rings the Closing Bell - Nasdaq
Maze Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat
Maze Therapeutics Inc (MAZE) 재무 분석
Maze Therapeutics Inc (MAZE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):